CSF2 and neoplasm: The approved Sipuleucel-T for the treatment of metastatic prostate cancer is generated by challenging ex vivo DCs with recombinant prostatic acid phosphatase (PAP) antigen fused with GM-CSF, which enhances antigen presentation and activation of T cells against tumor cells [93].